相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism
Paivi Lindholm et al.
MOLECULAR PSYCHIATRY (2022)
Disease modification in Parkinsonism: obstacles and ways forward
M. Hoellerhage et al.
JOURNAL OF NEURAL TRANSMISSION (2022)
Clinical experience of convection-enhanced delivery (CED) of carboplatin and sodium valproate into the pons for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults after radiotherapy
Elwira Szychot et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)
Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo
Katrina Albert et al.
MOLECULAR THERAPY (2021)
GDNF Therapy: Can We Make It Work?
Anders Bjorklund
JOURNAL OF PARKINSONS DISEASE (2021)
Cerebral dopamine neurotrophic factor-deficiency leads to degeneration of enteric neurons and altered brain dopamine neuronal function in mice
Maria Lindahl et al.
NEUROBIOLOGY OF DISEASE (2020)
Cerebral dopamine neurotrophic factor is essential for enteric neuronal development, maintenance, and regulation of gastrointestinal transit
Alcmene Chalazonitis et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2020)
Two Hundred Twenty-Six Consecutive Deep Brain Stimulation Electrodes Placed Using an Asleep Technique and the Neuro|Mate™ Robot for the Treatment of Movement Disorders
Catherine Moran et al.
OPERATIVE NEUROSURGERY (2020)
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop
Roger A. Barker et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Can Growth Factors Cure Parkinson's Disease?
Yulia A. Sidorova et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson's disease
Vera S. Kerstens et al.
EJNMMI RESEARCH (2020)
Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease
Alan Whone et al.
BRAIN (2019)
Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease
Alan L. Whone et al.
JOURNAL OF PARKINSONS DISEASE (2019)
CDNF Protein Therapy in Parkinson's Disease
Henri J. Huttunen et al.
CELL TRANSPLANTATION (2019)
Nigrostriatal dopamine transporter availability in early Parkinson's disease
Patrik Fazio et al.
MOVEMENT DISORDERS (2018)
DIPG-65. PRELIMINARY EXPERIENCE OF CHRONIC INTERMITTENT CONVECTION ENHANCED DELIVERY OF CARBOPLATIN AND VALPROIC ACID FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA FOLLOWING RADIATION THERAPY
Milo Hollingworth et al.
NEURO-ONCOLOGY (2018)
Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next?
Raymond T. Bartus et al.
NEUROBIOLOGY OF DISEASE (2017)
Parkinson disease
Werner Poewe et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Intrastriatally Infused Exogenous CDNF Is Endocytosed and Retrogradely Transported to Substantia Nigra
Kert Matlik et al.
ENEURO (2017)
Magnetic Resonance Imaging-Based Assessment of Gadolinium-Conjugated Diethylenetriamine Penta-Acetic Acid Test-Infusion in Detecting Dysfunction of Convection-Enhanced Delivery Catheters
Erik H. P. van Putten et al.
WORLD NEUROSURGERY (2016)
Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients
Gesine Paul et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Quantitative Analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease
Patrik Fazio et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
A Meta-analysis of the Complications Associated With Osseointegrated Hearing Aids
Ruwan Kiringoda et al.
OTOLOGY & NEUROTOLOGY (2013)
CDNF Protects the Nigrostriatal Dopamine System and Promotes Recovery After MPTP Treatment in Mice
Mikko Airavaara et al.
CELL TRANSPLANTATION (2012)
Automated Assessment of Bradykinesia and Dyskinesia in Parkinson's Disease
Robert I. Griffiths et al.
JOURNAL OF PARKINSONS DISEASE (2012)
Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease
Merja H. Voutilainen et al.
EXPERIMENTAL NEUROLOGY (2011)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
William J. Marks et al.
LANCET NEUROLOGY (2010)
Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease
Claire L. Tomlinson et al.
MOVEMENT DISORDERS (2010)
Clinical Measures of Progression in Parkinson's Disease
Werner Poewe
MOVEMENT DISORDERS (2009)
Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo
Pivi Lindholm et al.
NATURE (2007)
Point source concentration of GDNF may explain failure of phase II clinical trial
Michael F. Salvatore et al.
EXPERIMENTAL NEUROLOGY (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor
JT Slevin et al.
JOURNAL OF NEUROSURGERY (2005)
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
JG Nutt et al.
NEUROLOGY (2003)
The GDNF family: Signalling, biological functions and therapeutic value
MS Airaksinen et al.
NATURE REVIEWS NEUROSCIENCE (2002)
Neurotrophins: Roles in neuronal development and function
EJ Huang et al.
ANNUAL REVIEW OF NEUROSCIENCE (2001)
分享论文
